Article thumbnail

Design of a peptide-based vector, PepFect6, for efficient delivery of siRNA in cell culture and systemically in vivo

By Samir EL Andaloussi, Taavi Lehto, Imre Mäger, Katri Rosenthal-Aizman, Iulian I. Oprea, Oscar E. Simonson, Helena Sork, Kariem Ezzat, Dana M. Copolovici, Kaido Kurrikoff, Joana R. Viola, Eman M. Zaghloul, Rannar Sillard, Henrik J. Johansson, Fatouma Said Hassane, Peter Guterstam, Julia Suhorutšenko, Pedro M. D. Moreno, Nikita Oskolkov, Jonas Hälldin, Ulf Tedebark, Andres Metspalu, Bernard Lebleu, Janne Lehtiö, C. I. Edvard Smith and Ülo Langel


While small interfering RNAs (siRNAs) have been rapidly appreciated to silence genes, efficient and non-toxic vectors for primary cells and for systemic in vivo delivery are lacking. Several siRNA-delivery vehicles, including cell-penetrating peptides (CPPs), have been developed but their utility is often restricted by entrapment following endocytosis. Hence, developing CPPs that promote endosomal escape is a prerequisite for successful siRNA implementation. We here present a novel CPP, PepFect 6 (PF6), comprising the previously reported stearyl-TP10 peptide, having pH titratable trifluoromethylquinoline moieties covalently incorporated to facilitate endosomal release. Stable PF6/siRNA nanoparticles enter entire cell populations and rapidly promote endosomal escape, resulting in robust RNAi responses in various cell types (including primary cells), with minimal associated transcriptomic or proteomic changes. Furthermore, PF6-mediated delivery is independent of cell confluence and, in most cases, not significantly hampered by serum proteins. Finally, these nanoparticles promote strong RNAi responses in different organs following systemic delivery in mice without any associated toxicity. Strikingly, similar knockdown in liver is achieved by PF6/siRNA nanoparticles and siRNA injected by hydrodynamic infusion, a golden standard technique for liver transfection. These results imply that the peptide, in addition to having utility for RNAi screens in vitro, displays therapeutic potential

Topics: Synthetic Biology and Chemistry
Publisher: Oxford University Press
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (2007). 2’-O-methyl-modified RNAs act as TLR7 antagonists.
  2. (2008). A combinatorial library of lipid-like materials for delivery of RNAi therapeutics.
  3. (1999). A novel potent strategy for gene delivery using a single peptide vector as a carrier.
  4. (2009). A pH-sensitive fusogenic peptide facilitates endosomal escape and greatly enhances the gene silencing of siRNA-containing nanoparticles in vitro and in vivo.
  5. (2009). A stearylated CPP for delivery of splice correcting oligonucleotides using a non-covalent co-incubation strategy.
  6. (2009). Analysis of in vitro toxicity of five cell-penetrating peptides by metabolic profiling.
  7. (2007). Cargo-dependent cytotoxicity and delivery efficacy of cell-penetrating peptides: a comparative study.
  8. (1998). Cell penetrating PNA constructs regulate galanin receptor levels and modify pain transmission in vivo.
  9. (2007). Cell-penetrating-peptide-mediated siRNA lung delivery.
  10. (2008). Chemical modification patterns compatible with high potency dicer-substrate small interfering RNAs.
  11. (2009). Chemically modified cell-penetrating peptides for the delivery of nucleic acids.
  12. (1997). Chloroquine extends the lifetime of the activated insulin receptor complex in endosomes.
  13. (2008). Comprehensive mass-spectrometry-based proteome quantification of haploid versus diploid yeast.
  14. (2005). Core transcriptional regulatory circuitry in human embryonic stem cells.
  15. (2008). Delivery of proteins and nucleic acids using a non-covalent peptide-based strategy.
  16. (2007). Delivery of short interfering RNA using endosomolytic cell-penetrating peptides.
  17. (2006). Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo.
  18. (2008). Distinct uptake routes of cell-penetrating peptide conjugates.
  19. (2009). Efficient siRNA delivery into primary cells by a peptide transduction domain-dsRNA binding domain fusion protein.
  20. (2008). Enhancing the cellular uptake of siRNA duplexes following noncovalent packaging with protein transduction domain peptides.
  21. (2004). Hepatic uptake of negatively charged particles in rats: possible involvement of serum proteins in recognition by scavenger receptor.
  22. (1999). Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA.
  23. (2009). Induction of in vivo synthetic lethal RNAi responses to treat glioblastoma.
  24. (2007). Interfering with disease: a progress report on siRNA-based therapeutics.
  25. (2009). Knocking down barriers: advances in siRNA delivery.
  26. (2002). Massive and selective delivery of lipid-coated cationic lipoplexes of oligonucleotides targeted in vivo to hepatic endothelial cells.
  27. (2010). Nanoparticles for ex vivo siRNA delivery to dendritic cells for cancer vaccines: programmed endosomal escape and dissociation.
  28. (2008). Overcoming the innate immune response to small interfering RNA.
  29. (1998). Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans.
  30. (2008). Quantitative membrane proteomics applying narrow range peptide isoelectric focusing for studies of small cell lung cancer resistance mechanisms.
  31. (2002). RNA interference in adult mice.
  32. (2009). RNAi-based therapeutics-current status, challenges and prospects.
  33. (2006). RNAi-mediated gene silencing in non-human primates.
  34. (2008). Sequence- and target-independent angiogenesis suppression by siRNA via TLR3.
  35. (2005). Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7.
  36. (2010). Strategies in the design of nanoparticles for therapeutic applications.
  37. (2006). Structure-function correlation of chloroquine and analogues as transgene expression enhancers in nonviral gene delivery.
  38. (2008). T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice.
  39. (2009). Targeting cyclin B1 through peptide-based delivery of siRNA prevents tumour growth.
  40. (2009). The promises and pitfalls of RNA-interference-based therapeutics.
  41. (2010). Tissue-specific gene delivery via nanoparticle coating.
  42. (2007). Transvascular delivery of small interfering RNA to the central nervous system.
  43. (2009). Twenty years of cell-penetrating peptides: from molecular mechanisms to therapeutics.